Filing Flows › Treace Medical Concepts (TMCI) › Q3 2026
Treace Medical Concepts (TMCI) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 6, 2026
Treace Medical Concepts (TMCI) reported revenue of $48.3M for the third quarter 2026 (Q3 2026), -4% from a year earlier and +6% from the quarter before. Operating margin was -23.9%, net loss $12.6M (26.0% of revenue).
Treace Medical Concepts, Q3 2026: revenue $48.3M (-4% year over year), operating margin -23.9%, net loss $12.6M, operating cash flow −$3.3M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $48.3M | +6% | -4% |
| Operating profit | −$11.5M | — | — |
| Net earnings | −$12.6M | — | — |
| Operating cash flow | −$3.3M | — | — |
What changed
Revenue was $48.3M in Q3 2026, down 4% year over year and up 6% from the previous quarter.
Gross margin was 79.5%, up 0.4 points from Q3 2025. Operating costs exceeded revenue by $11.5M, an operating margin of -23.9%. Operating expenses fell 10% while revenue fell 4%. The quarter ended with a net loss of $12.6M, narrower than the previous quarter's $15.9M loss.
Operating cash flow was −$3.3M. Non-cash charges added back $2.0M of depreciation and amortization and $6.9M of share-based compensation. Working capital and other items added $348K. Capital expenditures of $2.2M exceeded it, leaving free cash flow of −$5.4M.
Questions
What was Treace Medical Concepts' revenue in the third quarter 2026?
Treace Medical Concepts (TMCI) reported revenue of $48.3M for the third quarter 2026 (Q3 2026), -4% from a year earlier and +6% from the quarter before.
Was Treace Medical Concepts profitable in the third quarter 2026?
Operating loss was $11.5M (-23.9% of revenue) and net loss $12.6M.